F2G is an England-based clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of rare fungal diseases. F2G was founded in 1998. F2G's headquarters is located in Manchester, England, GB M30 0LX. It has r... F2G's CEO, Francesco Maria Lavino, currently has an approval
rating of 90%. F2G's primary competitors are Cidara, Amplyx & Scynexis.
There have been no acquisitions found related to F2G
Recent investment data cannot be found related to F2G